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ABSTRACT
We have examined serum microRNA expression in multiple myeloma (MM) 
patients at diagnosis and at complete response (CR) after autologous stem-
cell transplantation (ASCT), in patients with stable monoclonal gammopathy of 
undetermined significance, and in healthy controls. MicroRNAs were first profiled 
using TaqMan Human MicroRNA Arrays. Differentially expressed microRNAs were 
then validated by individual TaqMan MicroRNA assays and correlated with CR 
and progression-free survival (PFS) after ASCT. Supervised analysis identified a 
differentially expressed 14-microRNA signature. The differential expression of miR-
16 (P = 0.028), miR-17 (P = 0.016), miR-19b (P = 0.009), miR-20a (P = 0.017) and 
miR-660 (P = 0.048) at diagnosis and CR was then confirmed by individual assays. 
In addition, high levels of miR-25 were related to the presence of oligoclonal bands 
(P = 0.002). Longer PFS after ASCT was observed in patients with high levels of 
miR-19b (6 vs. 1.8 years; P < 0.001) or miR-331 (8.6 vs. 2.9 years; P = 0.001). Low 
expression of both miR-19b and miR-331 in combination was a marker of shorter PFS 
(HR 5.3; P = 0.033). We have identified a serum microRNA signature with potential 
as a diagnostic and prognostic tool in MM.
INTRODUCTION
Multiple myeloma (MM), a malignant disorder 
characterized by the neoplastic growth of bone marrow 
plasma cells, accounts for 15% of all hematologic cancers 
[1, 2]. MM usually progresses from an asymptomatic 
premalignant state of clonal plasma cell proliferation 
known as monoclonal gammopathy of undetermined 
significance (MGUS) [3]. Although the introduction 
of new drugs, such as thalidomide, bortezomib and 
lenalidomide, has resulted in a superior complete 
response (CR) rate and longer progression-free survival 
(PFS) [4], MM is still an incurable disease. At present, 
the monitoring of response and progression requires an 
invasive procedure for the examination of bone marrow, 
since tumor cells are localized in the marrow and do not 
usually circulate in blood [5]. However, extramedullary 
disease cannot be accurately evaluated with bone marrow 
studies [6], and moreover, there is a need for non-invasive 
techniques for both the initial diagnosis and the follow-
up of patients with MM. To date, although serum-free 
light chain ratio [7] is a well-recognized biomarker for 
monitoring patients with MM and MGUS, only few other 
serum-based markers for MM have been incorporated into 
routine clinical practice.
MicroRNAs (miRNAs) are small endogenous non-
coding RNAs that regulate gene expression, mainly by 
inhibiting translation of specific target mRNAs. miRNAs 
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are involved in the regulation of several physiological and 
pathological processes, including tumorogenesis [8] and 
have emerged as promising prognostic biomarkers and as 
possible therapeutic targets [9]. Since it was first discovered 
that miRNAs can also be detected in serum or plasma 
[10, 11], research on circulating miRNAs has intensified and 
led to the development of a database of human circulating 
miRNAs [12]. In recent years, several studies have identified 
miRNA profiles in human myeloma cell lines and in 
primary patient samples, and the miRNA expression pattern 
has been associated with specific genetic abnormalities 
[13–16] and with patient survival [13, 17]. Interestingly, 
some miRNAs, such as the miR-17-92 cluster, are 
differentially expressed in multiple myeloma and MGUS 
[18]. The first promising biomarker detected in plasma from 
patients with MM was miR-92a, which was downregulated 
in MM but not in MGUS or smoldering MM [19]. Other 
studies have also identified several circulating miRNAs that 
show promise as potential prognostic or predictive markers 
[20–22]. Recently, miR-16 and miR-25 have been proposed 
as independent prognostic markers in newly diagnosed MM 
[23]. Taken together, these findings indicate that circulating 
serum miRNAs are an easily accessible, stable biomarker 
that could meet the need for a non-invasive method for 
monitoring patients with MM.
In order to further explore this potential role 
of circulating serum miRNAs, we have analyzed the 
expression of miRNAs in serum from three cohorts of 
individuals: paired samples from patients with MM at the 
time of diagnosis and of CR after autologous stem-cell 
transplantation (ASCT) (Table 1); samples from MGUS 
patients; and samples from healthy controls. In addition, 
in a subset of the patients with MM, we have compared 
miRNA expression levels at the time of CR and of relapse.
RESULTS
Screening phase: identification of miRNAs 
differentially expressed
The unsupervised hierarchical cluster analysis 
showed three major clusters with different patterns of 
miRNA expression (Figure 1A). The first cluster included 
all healthy control samples and three CR samples. The 
second cluster included three MGUS samples, eight CR 
samples and four diagnostic samples. Finally, the third 
cluster included 11 diagnostic samples and seven CR 
samples. A gradual decrease in overall miRNA expression 
levels was observed from the first to the third cluster 
(Figure 1A). PCA also distinguished between the three 
groups identified in the hierarchical cluster analysis 
(Figure 1B).
14-miRNA signature in multiple myeloma
Supervised analysis by SAM and t-test of the paired 
samples (diagnostic vs. CR) of 15 patients with MM 
revealed 14 miRNAs that were underexpressed in the 
diagnostic samples compared to the CR samples (Table 2). 
The hierarchical cluster analysis of these 14 miRNAs 
identified two clusters. The first cluster included 74% of 
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Figure 1: miRNA expression pattern in serum samples from patients with multiple myeloma (MM), patients with 
monoclonal gammopathy of undetermined significance (MGUS), and healthy controls. (A) Unsupervised hierarchical 
cluster analysis and (B) principal component analysis identified three major clusters with different patterns of miRNA expression. (C) 
Hierarchical cluster analysis of 14 miRNAs that were underexpressed in the diagnosis (Dx) samples compared to the complete remission 
(CR) samples from MM patients identified two clusters.
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the diagnostic samples, while the second cluster included 
67% of the CR samples (P = 0.06) (Figure 1C).
Validation phase I: confirmation of differential 
expression of miRNAs at diagnosis and at CR
miR-16, miR-17, miR-19b, miR-20a and miR-660 as 
markers of CR
The analysis of the 14 miRNAs identified in the 
screening phase confirmed the differential expression of 
five miRNAs between the diagnostic and CR samples of the 
patients with MM: miR-16 (P = 0.028), miR-17 (P = 0.016), 
miR-19b (P = 0.009), miR-20a (P = 0.017) and miR-660 
(P = 0.048) (Figure 2). Patients in CR showed a partial 
recovery of the normal serum levels of these five miRNAs. 
Levels in samples from MGUS patients were similar to 
those in CR samples but lower than healthy control samples 
(Figure 2). The ANOVA test showed significant differences 
between control, MGUS, diagnostic and CR samples in 
the expression levels of miR-16 (P < 0.001), miR-17 (P < 
0.001), miR-19b (P < 0.001), miR-20a (P = 0.002), miR-
660 (P < 0.001) and miR-25 (P < 0.001), with the highest 
levels of expression observed in samples from healthy 
controls. Although miR-25 was underexpressed in patients 
Table 1: Characteristics of the 33 patients with multiple myeloma included in the first part of the 
validation phase
Characteristic
Median age, yrs (range) 56 (25–66)
Gender (M/F) 13/20
Immunological subtype
 IgG 39.4%
 IgA 24.2%
 Light chains 24.2%
 Oligosecretory 3%
 Others 9.2%
Light chain subtype
 kappa 57.6%
 lambda 39.4%
International Staging System*
 I 51.6%
 II 32.3%
 III 16.1%
Median bone marrow plasma cells 44%
Extramedullary involvement 36.4%
Hemoglobin <10 g/L 21.2%
Calcium ≥11.5 mg/dL 12.1%
Creatinine ≥2 mg/dl 9.1%
Lytic bone lesions 66.7%
Induction treatment**
 Polychemotherapy (M2/VBAD, VAD, CY/Dex)
 Thalidomide/dexamethasone
 Bortezomib/thalidomide/dexamethasone
 Other bortezomib/dexamethasone-based
32.3%
19.3%
12.9%
35.5%
*Available in 31 patients
**One patient underwent autologous SCT without previous cytoreductive treatment and one received only local radiotherapy
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Figure 2: Differential serum levels of miR-16, miR-17, miR19b, miR-20a, miR-25 and miR-660 in patients with 
multiple myeloma (MM) at diagnosis (Dx) and at complete remission (CR), in patients with monoclonal gammopathy 
of undetermined significance (MGUS), and in healthy controls (HC).
Table 2: Significance analysis of microarrays (SAM) and Student’s t-test identified 14 miRNAs 
differentially expressed in serum from myeloma patients at diagnosis and the time of complete response
miRNA Adjusted P-value Fold Change
miR-16 2.244784E-4 0.005676097
miR-17 5.8513036E-5 0.0051784036
miR-18a 0.0074316533 0.03986069
miR-19b 2.913102E-4 0.0051561906
miR-20a 8.366445E-4 0.008710946
miR-20b 4.931529E-4 0.0067144665
miR-24 1.8698742E-4 0.0066193547
miR-25 6.002177E-4 0.0066399085
miR-27a 0.0011549154 0.010221002
miR-30b 5.4020213E-4 0.0068296986
miR-152 0.006841648 0.039063603
miR-331 9.056236E-4 0.008436599
miR-374 3.6963476E-5 0.0065425355
miR-660 5.7780603E-4 0.006818111
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with MM compared to MGUS patients and healthy controls, 
among patients with oligoclonal bands miR-25 expression 
was higher than in the other patients in CR without serum 
oligoclonal humoral response (P = 0.002). We also observed 
a trend towards lower miR-25 levels in diagnostic samples 
from patients with lytic bone lesions than in those without 
them (P = 0.07).
miR-19b and miR-133 as markers of PFS after CR
Twenty-eight of 33 patients with MM showed 
oligoclonal bands in serum and/or urine while in CR. At 
the time of analysis, 18 patients (54%) had relapsed after 
ASCT. Median PFS for all 33 patients was 5 years (95% 
CI, 2.2–73.8) and median overall survival was not reached 
(estimated survival at 5 years, 88.7%).
Shorter PFS was associated with low miR-19b 
levels (median 1.8 vs. 6 years; P < 0.001) and low miR-
331 levels (median 2.9 vs. 8.6 years; P = 0.001) at the 
time of CR (Figure 3). Moreover, when we examined the 
combinatory effect of these two miRNAs, we found that 
PFS was shorter (P < 0.001) in patients with low levels of 
both miRNAs than in those with high levels of either one 
(Figure 4).
In the univariate analysis, only older age (>55 
years), high creatinine levels (>2 mg/dL), and low miR-
19b/miR-331 expression were associated with shorter 
PFS. The multivariate analysis identified the miR-19b/
miR-331 combination (HR, 5.3; 95% CI, 1.1–24.7; P = 
0.033) and creatinine levels (HR, 7.5; 95% CI, 1.9–29.7; 
P = 0.004) as prognostic markers of PFS.
Figure 4: Progression-free survival after autologous stem-cell transplantation according to the expression levels of 
miR-19b and miR-331, comparing patients with low levels of both miRNAs and those with high expression of either 
miRNA.
Figure 3: Progression-free survival after autologous stem-cell transplantation according to (A) miR-19b and (B) miR-
331 expression levels in serum.
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Validation phase II: comparison of serum 
miRNA levels at CR and at relapse
In the subset of 17 patients with paired serum 
samples at CR and at relapse, we examined the expression 
levels of the miRNAs that had been related to CR or PFS 
in the first part of the validation phase. Significantly lower 
levels of miR-19b were observed in samples obtained 
at relapse than in those obtained at CR (P = 0.04). A 
non-significant trend towards a difference in miR-331 
expression was observed, and there were no significant 
differences between expression levels of miR-16, miR-17, 
miR-20a, miR-25 or miR-660.
DISCUSSION
Biomarkers have a clear role in assessing response 
to treatment and prognosis in patients with malignant 
monoclonal gammopathies, as well as in therapeutic 
decision-making and early diagnosis in oligosymptomatic 
cases [24]. When these biomarkers can be examined in 
plasma or serum, they can potentially be used to evaluate 
both medullar and extramedullar disease at different 
time points in a non-invasive manner. For example, 
serum-free light chain assay is a commonly used method 
for monitoring patients [25], and recently, other more 
innovative techniques have been described, including next 
generation sequencing in peripheral blood [26], proteomics 
for sensitive measuring of M-protein [27], and circulating 
miRNAs [23]. Circulating miRNAs are particularly 
promising biomarkers, since they remain stable for long 
periods of time, are relatively easy to measure, and reflect 
the entire tumor mass, including plasma cells that are 
either absent or patchy in bone marrow [28].
In the present study, we have quantified circulating 
miRNAs in serial serum samples from patients with 
MM and in samples from MGUS patients and healthy 
controls and have identified a 14-miRNA signature which 
was underexpressed in patients with MM, while MGUS 
patients showed an intermediate expression level between 
patients with MM and healthy controls. Moreover, the 
expression of five of these miRNAs – miR-16, miR-17, 
miR-19b, miR-20a and miR-660 – increased at the time 
of CR, and two of the 14 miRNAs – miR-19b and miR-
331 – were linked to PFS after ASCT. Patients with lower 
levels of miR-19b or miR-331 had shorter PFS than 
those with higher levels, and moreover, those with low 
levels of both miRNAs had shorter PFS than those with 
high levels of either miRNA. Importantly, the miR-19b/
miR-331 combination retained its prognostic value in the 
multivariate analysis (HR, 5.3; P = 0.033).
The components of the 14-miRNA signature can 
be classified in five expression clusters: miR-16, miR-
17-92 cluster and paralogs, miR-23/24/27a, miR-331 and 
miR-660. The origin and mechanism of action of these 
miRNAs are not clear; however, since all 14 miRNAs 
are downregulated in serum, we can speculate that their 
origin is not in the tumor cell. In fact, serum miRNA 
showed no correlation with intracellular levels in 
malignant bone marrow plasma cells in paired samples 
[23]. Several cells, including those in blood and in the 
bone marrow microenvironment, can release miRNAs 
or modify their expression in response to MM. It is 
well known that almost 80% of MM patients develop 
osteolytic lesions. MM cells stimulate bone resorption 
by enhancing osteoclastogenesis, while suppressing bone 
formation by inhibiting osteoblastic differentiation from 
bone marrow stromal cells, leading to extensive bone 
destruction with rapid bone loss [29]. Several miRNAs 
included in our 14-miRNA signature have previously 
been related to osteoblasts, leading us to speculate that 
their downregulation in patients with MM could be 
due to the reduction of osteoblasts associated with the 
disease. For example, miR-16 has previously been found 
elevated during osteoclast/osteoblast differentiation [30] 
and its ectopic expression in serum correlated with bone 
metastasis burden in breast cancer [31]. In addition, the 
miR-17-92 cluster and paralogs, which includes miR-
25, have been related to the regulation of osteoblast 
proliferation and differentiation [32] and to the promotion 
of hematopoietic cell expansion by augmenting HIF-1a 
in osteoblasts [33]. Interestingly, a mouse model with 
deletion of miR-17-92 cluster showed reduced skeletal 
growth with delayed ossification likely due to impaired 
osteoblast proliferation and differentiation [34]. Along 
these lines, in the present study, there was a trend towards 
lower levels of miR-25 in patients who had bone lesions 
at diagnosis. Finally, miR-27, part of the miR-23/24/27a 
cluster, activates the Wnt signaling pathway, affecting the 
differentiation of mesenchymal stem cells into osteoblasts 
[35]. All these data suggest a potential role for the 
osteoblast/osteoclast axis in circulating miRNA levels 
that should be explored in prospective studies along with 
bone remodeling biomarkers. miRNAs can be contained 
within exosomes, and our knowledge of their role in 
communication between cells is growing. These vesicles 
of endocytic origin can be released by many types of cells, 
facilitating several biological processes [36]. In fact, bone 
marrow mesenchymal cells can deliver exosomes to MM 
cells, and exosomes from patients with MM have lower 
levels of the tumor suppressor miR-15 and higher levels 
of oncogenic proteins, cytokines, and adhesion molecules 
[37]. This highlights the importance of the bone marrow 
microenvironment in miRNA homeostasis in MM activity 
and remission.
In our patients with MM, several miRNAs were 
underexpressed in serum at diagnosis but increased at 
CR; moreover, miR-19b and miR-331 were associated 
with shorter PFS. Our findings are in line with several 
other studies relating miRNAs, including those in our 
14-miRNA signature (Table 2) and others, to prognosis 
in MM and other hematological and solid tumors. For 
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example, downregulation of circulating miR-16 and 
miR-25 were related to poor prognosis in multiple 
myeloma [23]. Interestingly, miR-16 has a tumor 
suppressor role in MM pathogenesis by targeting clonal 
plasma cells, reducing bone marrow neoangiogenesis 
and reducing interaction between the tumor cells and the 
bone marrow. miR-16 induced a 60% reduction in MM 
cells proliferation at 72 h after pre-miR-16 transfection 
[38]. Moreover, downregulation of miR-331-5p and 
miR-27a was associated with chemotherapy resistance 
and relapse in leukemia [39]. Downregulation of 
circulating miR-660 has been reported in plasma from 
lung cancer patients [40].
In another study, three miRNAs (miR-720, miR-
1308 and miR-1246) showed a good specificity in 
distinguishing MM or MGUS from healthy individuals 
and also in differentiating MM from MGUS [21]. A 
microarray analysis found six miRNAs (miR-148a, 
miR-181a, miR-20a, miR-221, miR-625 and miR-99b) 
that were upregulated in patients with MM compared 
to healthy controls [20]; miR-221 and miR-99b were 
related to the karyotype of the disease, whereas miR-
148a and miR20a were related to relapse-free survival 
[20]. Recently, Kubiczkova et al have identified a miRNA 
profile deregulated in MM and MGUS serum, where miR-
744, miR-130a, let-7d and let-7e levels were decreased 
and miR-34a levels were increased in MM and MGUS 
when compared to healthy controls [22]. Additionally, 
miR-744 and let-7e levels were biomarkers of overall 
survival [22].
Our study differs in scope from previously reported 
series, particularly that by an Italian group in 54 patients 
[23]. Firstly, all of our 33 patients underwent ASCT, 
while the patients in the Italian study were older and 
thus ineligible for stem-cell transplantation. In addition, 
the main goal in the Italian study was to examine the 
prognostic impact of the serum expression of miR-16 
and miR-25 at diagnosis, together with cytogenetics by 
FISH and ISS, which were already well established as 
prognostic factors, and to compare the expression of 
these miRNAs in 32 paired samples of serum and bone 
marrow plasma cells. In contrast, we have compared the 
serum miRNA profile in paired samples at diagnosis and 
at the time of CR in order to define the prognostic impact 
of serum miRNA for patients in CR. Since a long-lasting 
CR is crucial for survival of patients with MM [41, 42], 
serum biomarkers to predict the duration of CR are clearly 
relevant in this setting.
As with all studies, ours has several limitations. 
Since we selected patients with samples at the time of 
CR, our series was enriched with more sensitive patients 
and our findings should be explored in refractory and 
high-risk patients, particularly those with extramedullary 
disease. In addition, the retrospective nature of our study 
and the relatively small number of patients included 
make it difficult to draw definitive conclusions from our 
findings; further studies in our cooperative Spanish group 
and prospective validation in sequential samples are 
therefore warranted. However, despite these limitations, 
our results highlight the potential value of serum miRNAs 
as diagnostic and prognostic biomarkers in MM and pave 
the way for further studies of our 14-miRNA signature in 
larger, more varied patient cohorts.
PATIENTS AND METHODS
Study design and patients
The study consisted of an initial screening phase, 
followed by a two-part validation phase. The objective of 
the screening phase was to identify miRNAs differentially 
expressed in serum samples from patients with MM at the 
time of diagnosis, the same patients at the time of CR, 
MGUS patients, and healthy controls. In the first part 
of the validation phase, the miRNAs identified in the 
screening phase were analyzed individually to confirm 
their differential expression between patient samples at 
diagnosis and at CR. Finally, in a subset of patients, the 
second part of the validation phase compared miRNA 
expression at the time of CR and of relapse.
The screening phase included 15 patients with MM, 
four patients with stable MGUS (>5 years of follow-up), 
and five healthy controls. Paired serum samples were 
obtained from the patients with MM at diagnosis and at 
the time of confirmed CR after melphalan-based ASCT.
In the first part of the validation phase, a total of 33 
patients with MM, eight MGUS patients and eight healthy 
controls were included. The main clinical characteristics 
of the patients with MM are summarized in Table 1. 
Median follow-up for alive patients was four years (range, 
1–14). In these patients, cytogenetic abnormalities by 
FISH in bone marrow plasma cells were t(4;14) in four, 
t(11;14) in four, t(14;16) in one, and del17p in one patient. 
Nine patients had del13q by conventional karyotype. 
Information on time to relapse after ASCT, further 
treatment and follow-up was collected for all patients. The 
second part of the validation phase was performed on the 
subset of 17 patients with MM with available paired serum 
samples at CR and at the time of relapse after ASCT.
Response and relapse were defined according to 
European Blood and Marrow Transplantation criteria [43]. 
In short, CR required the disappearance of the original 
myeloma protein in serum and urine immunofixation (IFE) 
and less than 5% bone marrow plasma cells. In patients 
with CR, relapse was defined by recurrence of detectable-
component on IFE, even if electrophoresis remained 
negative, excluding oligoclonal immune reconstitution.
Written informed consent was obtained from 
each participant in accordance with the Declaration of 
Helsinki and the Ethics Committee of Hospital Clínic of 
Barcelona provided institutional review board approval 
for this study.
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RNA extraction and miRNA quantification
RNA was extracted from frozen serum samples 
using miRNeasy Mini Kit (Qiagen). In the screening 
phase, 380 miRNAs and controls were profiled 
using TaqMan Human MicroRNA Arrays (Array A; 
Applied Biosystems) using pre-amplification as per 
the manufacturer’s protocol. Expression levels were 
calculated by the 2-∆∆Ct method. Real-time quantitative 
PCR reactions were performed on an ABI 7900 HT 
Sequence Detection System (Applied Biosystems). miR-
483-5p was used as endogenous control, since this miRNA 
had the smallest standard deviation among samples and 
showed no statistical differences in its expression levels 
between patients and healthy controls. The median level 
of healthy controls was used as calibrator. All miRNAs 
that expressed <10% or with an unreliable quantification 
were excluded from further analysis, leaving a set of 177 
miRNAs.
In the validation phases, miRNAs differentially 
expressed between diagnosis and CR or between CR and 
relapse were selected for validation by single Real Time 
TaqMan® MicroRNA Assays (without pre-amplification) 
in an Applied Biosystems 7500 Sequence Detection 
System as previously described [44, 45].
Statistical analysis
In the screening phase, data on miRNA expression 
were analyzed using BRB Array Tools version 
3.5.0 software (Richard Simon & BRB-ArrayTools 
Development Team, http://linus.nci.nih.gov/BR-
ArrayTools.html), TIGR Multiexperiment viewer version 
4.0 software (The Institute for Genomic Research, and 
ArrayAssist software, Stratagene, http://www.tm4.org/
mev), R software version 2.15.2 (The R Foundation 
for Statistical Computing c/o Institute for Statistics and 
Mathematics, Wirtschaftsuniversität Wien, http://www.-
project.org/) and GraphPad software 5.0 (GraphPad 
Software Inc., San Diego, CA, USA, http://www.graphpad.
com/). Hierarchical clustering (using Manhattan distance 
and average linkage) and principal component analysis 
(PCA) were used to classify samples. To identify miRNAs 
with significant differential expression between groups, 
two multivariate permutation tests were performed: 
significance analysis of microarrays (SAM) and Student’s 
t-test based on multivariate permutation (with random 
variance model). Differences between miRNAs in the 
screening phase of the study were considered statistically 
significant if the t-test showed P < 0.001 or SAM showed 
a false discovery rate of <0.1% (Supplementary Table 1). 
A final miRNA signature comprised miRNAs that were 
identified by both methods.
In the validation phases, the expression levels of 
individual miRNAs were compared between groups 
using paired or unpaired t-test or ANOVA analysis for 
continuous variables. For patients with CR, PFS was 
defined as survival from the time of ASCT until relapse 
or death from any cause. Overall survival was calculated 
from the time of ASCT to last follow-up or death from 
any cause. Optimal cutoffs of miRNA expression were 
assessed by means of maximally selected log-rank 
statistics using the Maxstat package (R package). Survival 
probabilities were estimated using the Kaplan-Meier 
method and compared by means of the log-rank test. The 
Cox proportional hazards model was used to estimate 
the hazard ratios (HR) with their respective confidence 
intervals (CIs) after controlling for prognostic variables.
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